Integrated Quantitative Investments LLC Purchases Shares of 11,916 Illumina, Inc. $ILMN

Integrated Quantitative Investments LLC bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 11,916 shares of the life sciences company’s stock, valued at approximately $1,132,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. Generali Asset Management SPA SGR raised its holdings in shares of Illumina by 51.6% during the 3rd quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock worth $2,113,000 after acquiring an additional 7,574 shares in the last quarter. Andra AP fonden increased its stake in Illumina by 426.3% in the 2nd quarter. Andra AP fonden now owns 102,491 shares of the life sciences company’s stock worth $9,779,000 after buying an additional 83,017 shares during the period. Aaron Wealth Advisors LLC lifted its holdings in Illumina by 342.6% during the 3rd quarter. Aaron Wealth Advisors LLC now owns 10,476 shares of the life sciences company’s stock valued at $995,000 after buying an additional 8,109 shares in the last quarter. Douglas Lane & Associates LLC raised its stake in shares of Illumina by 6.6% during the third quarter. Douglas Lane & Associates LLC now owns 307,609 shares of the life sciences company’s stock valued at $29,214,000 after acquiring an additional 18,914 shares in the last quarter. Finally, Nordea Investment Management AB lifted its holdings in shares of Illumina by 148.6% in the 3rd quarter. Nordea Investment Management AB now owns 32,657 shares of the life sciences company’s stock worth $3,024,000 after buying an additional 19,519 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Performance

Shares of ILMN stock opened at $128.97 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. The company has a market cap of $19.72 billion, a P/E ratio of 23.66, a P/E/G ratio of 2.48 and a beta of 1.45. Illumina, Inc. has a one year low of $68.70 and a one year high of $155.53. The firm has a 50-day moving average of $134.74 and a 200-day moving average of $118.89.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the prior year, the business posted $0.95 earnings per share. The business’s quarterly revenue was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president owned 16,321 shares in the company, valued at $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the transaction, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. The trade was a 1.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 2.60% of the company’s stock.

Analyst Upgrades and Downgrades

ILMN has been the topic of several research reports. Piper Sandler cut their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. TD Cowen reaffirmed a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Canaccord Genuity Group boosted their price target on Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a research report on Monday, January 26th. JPMorgan Chase & Co. cut their target price on Illumina from $130.00 to $120.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Finally, Barclays increased their target price on shares of Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research report on Monday, December 15th. Six analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $129.69.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.